WithdrawnPhase 2

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Stopped: No patients were able to be screened nor enrolled.

United States0Started 2020-02-12

Plain-language summary

In this trial the investigators aim to evaluate safety and efficacy of combination Ivosidenib (AG-120) and nivolumab in the context of adult patients with Isocitrate dehydrogenase-1 (IDH1) mutated acute myeloid leukemias (AML) or Myelodysplastic syndromes (MDS).

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients post allogeneic transplantation may be included on the trial if they are:
✕. 6 months from transplantation
✕. not actively on any immunosuppressive therapy
✕. without evidence of acute or chronic GVHD.

What they're measuring

Overall response rate

Timeframe: 168 days

Change in duration of response

Timeframe: 12 months

Trial details

NCT IDNCT04044209

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-09

View on ClinicalTrials.gov More Myelodysplastic Syndromes trials